サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1735697

はしか、おたふくかぜ、風疹ウイルスワクチンの世界市場規模：患者タイプ別、流通チャネル別、地域範囲別および予測

Global Measles, Mumps, And Rubella Virus Vaccine Market Size By Patient Type, By Distribution Channel, By Geographic Scope And Forecast

出版日
ページ情報
英文 202 Pages
納期
2～3営業日
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.76円
はしか、おたふくかぜ、風疹ウイルスワクチンの世界市場規模：患者タイプ別、流通チャネル別、地域範囲別および予測
出版日: 2025年05月02日
発行: Verified Market Research
ページ情報: 英文 202 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

はしか、おたふくかぜ、風疹ウイルスワクチンの市場規模と予測

はしか、おたふくかぜ、風疹ウイルスワクチンの市場規模は、2024年に8億1,956万米ドルと評価され、2026年から2032年の予測期間中にCAGR 3.90 %で成長し、2032年には11億1,303万米ドルに達すると予測されています。

はしか、おたふくかぜ、風疹ウイルスワクチンの世界市場促進要因

はしか・おたふく風邪・風疹ウイルスワクチン市場の市場促進要因は、様々な要因に影響される可能性があります。これらには以下のようなものが含まれます：

  • 政府の予防接種プログラム：MMRワクチンの需要を押し上げる主な要因は、はしか、おたふくかぜ、風疹を含む感染症の蔓延を食い止めることを目的とした予防接種キャンペーンに対する各国政府の関心の高まりと資金援助です。
  • 教育と意識の高まり：予防接種の価値や、予防接種が特定の病気の予防に役立つことを人々が認識するようになれば、需要は高まると思われます。MMRワクチンの利点について一般の人々の認識を高める上で最も重要な役割のひとつは、NGO、政府組織、ヘルスケア専門家による活動です。
  • 病気の発生率の増加：予防接種の必要性は、世界各地で発生しているはしか、流行性耳下腺炎、風疹によって高まっています。また、一部の地域でワクチン接種率が低下した結果、これらの病気が再発する可能性が懸念されていることも、市場拡大に拍車をかけています。
  • 技術の進歩：ワクチン技術における継続的な研究開発により、より安全で効果的なMMRワクチンが開発されています。市場の拡大は、1回の接種で複数の病気を予防できる混合ワクチンの開発などの技術革新によって支えられています。
  • 世界化と旅行：世界の渡航の増加と世界化の結果、はしか、流行性耳下腺炎、風疹などの感染症が蔓延しており、これらの病気に対する予防接種は、渡航者や渡航の多い地域の住民にとって不可欠となっています。
  • 公衆衛生上の緊急事態：パンデミックやアウトブレイクのようにワクチンで予防可能な病気が発生すると、予防接種プログラムが重視される結果、MMRワクチン接種の需要が高まる。
  • 政府の義務や法律：MMRワクチンの需要は、就学や特定の国への渡航に必要なワクチン接種に関する政府の厳しい法律や義務化によって牽引されています。
  • ヘルスケア・インフラへの投資：ヘルスケアインフラへの投資は、予防接種サービスへのアクセスを向上させ、MMRワクチンの需要を増加させます。これは特に新興経済国で顕著です。

はしか、おたふくかぜ、風疹ウイルスワクチンの世界市場抑制要因

はしか・おたふくかぜ・風疹ウイルスワクチン市場にとって、いくつかの要因が市場抑制要因や課題として作用する可能性があります。これらには以下が含まれる：

  • 誤報とワクチンへのためらい：ワクチンの有効性、安全性、起こりうる副作用に関する誤った情報や心配によって煽られます。ワクチン接種率の低下やMMRワクチン市場の縮小は、この結果もたらされる可能性があります。
  • サプライチェーンの困難：特に農村部や資源の乏しい地域では、ワクチンの流通や保管にコールドチェーンが必要であるなど、複雑なサプライチェーンや物流の困難さによって、MMRワクチンの入手や利用が妨げられる可能性があります。
  • 高い製造コスト：MMRワクチンの価格と入手可能性は、特に低・中所得国におけるワクチン製造の高コストと、厳しい規制規制や品質管理基準のために制限される可能性があります。
  • 世界経済の不確実性：MMRワクチンの需要減退は、景気後退、通貨変動、ヘルスケア支出の予算制限に起因する可能性があり、これらは政府、ヘルスケアプロバイダー、個人にとってのワクチンの値ごろ感に影響します。
  • ワクチン開発における障害：新規のMMRワクチンや改良型MMRワクチンの市場開拓は、開発スケジュールの長期化、規制上の障壁、継続的な研究と技術革新の必要性などの障害によって制限される可能性があります。
  • 競合環境：古くからある企業や最近参入した企業を含め、ワクチン製造業者間の競争は激しく、価格への圧力や利益率の低下を招き、市場拡大や研究開発費の妨げとなる可能性があります。
  • 法的・規制的障害：特許争奪戦、知的財産権、規制当局の承認手続きなどを含むこれらの障害は、新規ワクチンの市場参入を妨げたり、新規予防接種の開始を延期したりする可能性があり、MMRワクチン市場全体の成長に影響を与える可能性があります。
  • 倫理的・文化的要因：はしか・流行性耳下腺炎・風疹の高いワクチン接種率を達成するためには、倫理的懸念、文化的見解、ワクチン接種に対する宗教的反対などが妨げとなる可能性があります。これらの要因は、特に特定の地域やコミュニティにおけるワクチンの受け入れや摂取に影響を与える可能性があります。

目次

第1章 世界のはしか・おたふくかぜ・風疹ウイルスワクチン市場の導入

  • 市場概要
  • 調査範囲
  • 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

  • データマイニング
  • バリデーション
  • 一次資料
  • データソース一覧

第4章 世界のはしか・おたふくかぜ・風疹ウイルスワクチン市場展望

  • 概要
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • ポーターのファイブフォースモデル
  • バリューチェーン分析

第5章 はしか・おたふく風邪・風疹ウイルスワクチンの世界市場：患者タイプ別

  • 概要
  • 小児患者
  • 成人患者

第6章 はしか・おたふく風邪・風疹ウイルスワクチンの世界市場：流通チャネル別

  • 概要
  • 病院薬局
  • ドラッグストア
  • 小売薬局
  • 予防接種センター

第7章 はしか・おたふく風邪・風疹ウイルスワクチンの世界市場：地域別

  • 概要
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他の欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • その他のアジア太平洋
  • 世界のその他の地域
    • ラテンアメリカ
    • 中東・アフリカ

第8章 世界のはしか・おたふくかぜ・風疹ウイルスワクチン市場の競合情勢

  • 概要
  • 各社の市場ランキング
  • 主な開発戦略

第9章 企業プロファイル

  • MedImmune
  • Johnson & Johnson Private Limited
  • Merck & Co., Inc
  • Sanofi
  • Serum Institute of India Pvt. Ltd
  • Bavarian NordicAstellas Pharma India Private Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • JC Medical

第10章 付録

  • 関連調査
目次
Product Code: 35927

Measles, Mumps, And Rubella Virus Vaccine Market Size And Forecast

Measles, Mumps, And Rubella Virus Vaccine Market size was valued at USD 819.56 Million in 2024 and is projected to reach USD 1113.03 Million by 2032, growing at a CAGR of 3.90 % during the forecast period 2026-2032.

Global Measles, Mumps, And Rubella Virus Vaccine Market Drivers

The market drivers for the Measles, Mumps, And Rubella Virus Vaccine Market can be influenced by various factors. These may include:

  • Government Immunisation Programmes: A major factor driving up demand for MMR vaccines is governments' increased attention to and funding of immunisation campaigns aimed at stopping the spread of infectious diseases including the measles, mumps, and rubella.
  • Growing Education and Awareness: As people become more aware of the value of immunisation and how it helps avoid certain diseases, demand will rise. One of the most important roles in raising public awareness of the advantages of the MMR vaccine is the work done by NGOs, government organisations, and healthcare professionals.
  • Increasing Disease Incidence: The need for vaccinations is being driven by measles, mumps, and rubella outbreaks in different parts of the world. Market expansion is also fueled by worries about these illnesses' potential to resurface as a result of falling vaccination rates in some areas.
  • Technological Advancements: Ongoing research and development in vaccine technology results in the creation of MMR vaccines that are safer and more effective. Market expansion is aided by innovations like the creation of combination vaccinations, which provide protection against several illnesses with a single dose.
  • Globalisation and Travel: As a result of increased worldwide travel and globalisation, infectious diseases such as measles, mumps, and rubella are spreading, making immunisation against these diseases essential for travellers and residents of high-travel regions.
  • Public Health Emergencies: When diseases that are vaccine-preventable, like pandemics or outbreaks, occur, the demand for MMR vaccinations rises as a result of the emphasis placed on immunisation programmes.
  • Government Mandates and Laws: The demand for MMR vaccines is driven by governments' strict laws and mandates pertaining to vaccination requirements for school enrollment or travel to specific countries.
  • Investments in Healthcare Infrastructure: Investing in healthcare infrastructure increases access to immunisation services, which in turn increases demand for MMR vaccines. This is particularly true in emerging economies.

Global Measles, Mumps, And Rubella Virus Vaccine Market Restraints

Several factors can act as restraints or challenges for the Measles, Mumps, And Rubella Virus Vaccine Market. These may include:

  • Misinformation and Vaccine Hesitation: One major obstacle is vaccine hesitation, which is stoked by false information and worries about the efficacy, safety, and possible side effects of vaccines. Lower vaccination rates and a decline in the market for MMR vaccinations may result from this.
  • Supply Chain Difficulties: Especially in rural or resource-poor locations, the availability and accessibility of MMR vaccines may be hampered by complicated supply chains and logistical difficulties, such as the need for cold chain conditions for vaccine distribution and storage.
  • High Manufacturing Costs: The price and accessibility of MMR vaccines may be restricted due to the high cost of manufacturing vaccines, especially in low- and middle-income countries, as well as strict regulatory regulations and quality control standards.
  • Global Economic Uncertainty: Decreases in demand for MMR vaccines can result from economic downturns, currency changes, and budgetary limits in healthcare spending that affect the affordability of vaccines for governments, healthcare providers, and individuals.
  • Obstacles in the Development of Vaccinations: The market availability of novel and enhanced MMR vaccinations may be restricted by obstacles in the form of lengthy development schedules, regulatory barriers, and the requirement for ongoing research and innovation.
  • Competitive Environment: High levels of rivalry among vaccine producers, including both long-standing firms and recent arrivals, can lead to pressure on prices and narrowed profit margins, which impedes market expansion and R&D spending.
  • Legal and Regulatory Barriers: These obstacles, which include patent battles, intellectual property rights, and regulatory approval procedures, can impede the entry of new vaccines into the market or postpone the launch of new vaccinations, which can have an impact on the MMR vaccine market's overall growth.
  • Ethical and Cultural Factors: Obtaining high vaccination coverage rates for measles, mumps, and rubella can be hampered by ethical concerns, cultural views, and religious objections to vaccination. These factors can especially affect vaccine acceptance and uptake in certain communities or areas.

Global Measles, Mumps, And Rubella Virus Vaccine Market Segmentation Analysis

The Global Measles, Mumps, And Rubella Virus Vaccine Market are Segmented on the Patient Type, Distribution Channel, and Geography.

Measles, Mumps, And Rubella Virus Vaccine Market, By Patient Type

  • Pediatric Patient
  • Adult Patient

Based on Patient Type, the market is segmented into Pediatric Patient and Adult Patient. Pediatric vaccines are given in two dosages. First at 15 years old months and the second is before the age of six. Pediatric vaccines are more viable than adult vaccines. The adult vaccines are just a solitary portion of vaccination. As per CDC, grown-ups brought into the world in 1957 or later who have not been immunized or have not had measles are suggested one portion of the measles vaccine. The pediatric vaccine portion is assessed to represent a significant portion of the worldwide Measles, Mumps, And Rubella Virus Vaccine Market.

Measles, Mumps, And Rubella Virus Vaccine Market, By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores
  • Retail Pharmacies
  • Vaccination Center

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Drug Stores, Vaccination Center, and Retail Pharmacies. Vaccination centers are the most trusted channel for vaccination after that people prefer hospital pharmacies for vaccinations.

Measles, Mumps, And Rubella Virus Vaccine Market, By Geography

  • North America
  • Europe
  • Asia Pacific
  • Rest of the world
  • On the basis of Geography, the global Measles, Mumps, And Rubella Virus Vaccine Market is classified into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America holds the main share in the Measles, Mumps, And Rubella Virus Vaccine Market. A key factor driving the development of the market in the area is far-reaching government drives for vaccination against viral sicknesses. The Asia Pacific is arising as a critical district in the Measles, Mumps, And Rubella Virus Vaccine Market. Rising mindfulness among people of low monetary layers in agricultural nations of the district is a key factor impelling the measles, mumps, and rubella antibody market in the area.

Key Players

  • The major players in the Measles, Mumps, And Rubella Virus Vaccine Market are:
  • MedImmune
  • Johnson & Johnson Private Limited
  • Merck & Co. Inc.
  • Sanofi
  • Serum Institute of India Pvt. Ltd.
  • Bavarian NordicAstellas Pharma India Private Limited
  • CSL Limited
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline plc
  • JC Medical

Key Developments

  • In August 2021, Researchers from South Africa started a clinical experiment to see if the MMR vaccine for children may shield front-line medical staff from the Covid-19 virus or lessen the severity of the disease for individuals who contract it. Scientists from the Universities of the Witwatersrand (UW) and Cape Town (UCT) in South Africa started the trials.
  • In August 2021, GSK applied for PRIORIX (Measles, Mumps, and Rubella Virus Vaccine, Live) to be used in active immunization against measles, mumps, and rubella (MMR) infection by submitting an application for a biologic license (BLA) with the US Food and Drug Administration (FDA).
  • Ace Matrix Analysis
  • The ace matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Measles, Mumps, And Rubella Virus Vaccine Market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the global Measles, Mumps, And Rubella Virus Vaccine Market, gauge the attractiveness of a certain sector, and assess investment possibilities

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY PATIENT TYPE

  • 5.1 Overview
  • 5.2 Pediatric Patient
  • 5.3 Adult Patient

6 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
  • 6.2 Hospital Pharmacies
  • 6.3 Drug Stores
  • 6.4 Retail Pharmacies
  • 6.5 Vaccination Center

7 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Rest of the World
    • 7.5.1 Latin America
    • 7.5.2 Middle East And Africa

8 GLOBAL MEASLES, MUMPS, AND RUBELLA VIRUS VACCINE MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Development Strategies

9 COMPANY PROFILES

  • 9.1 MedImmune
    • 9.1.1 Overview
    • 9.1.2 Financial Performance
    • 9.1.3 Product Outlook
    • 9.1.4 Key Developments
  • 9.2 Johnson & Johnson Private Limited
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Merck & Co., Inc
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Sanofi
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 Serum Institute of India Pvt. Ltd
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Bavarian NordicAstellas Pharma India Private Limited
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 CSL Limited
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 Emergent BioSolutions Inc.
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 GlaxoSmithKline plc
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 JC Medical
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 Appendix

  • 10.1 Related Research